Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,449 total articles
Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, has appointed Tzvi Lev as Head of Sales for the Middle East to spearhead commercial expansion across the Gulf Cooperation Council and Israel. Leveraging Lev's extensive defense, diplomatic, and regional market experience, the company aims to convert its advanced autonomous d…
FuelCell Energy reported Q3 FY2026 results highlighting a substantial increase in its backlog to $3.6 billion driven by new agreements including a major data center power supply contract. The company is progressing its manufacturing facility expansion to target 500 MW annualized capacity by 2028 and aims for positive Adjusted EBITDA by Q4 FY2027. S…
Algoma Steel Group Inc. reports progress on managing the unplanned outage at its Lake Superior Power generating facility. Through interim measures coordinated with Ontario's electricity operator, the company has resumed electric arc furnace production and is pursuing options to repair or replace the affected turbine. Algoma continues to evaluate pr…
Cronos Group Inc. announced an expansion of its Spinach® brand product line, introducing new edible multipacks featuring their first live resin gummy and new vape cartridge flavors. These additions build on Spinach®'s position as Canada's leading edible and vape brand, with planned broader national availability.
Zevra Therapeutics, a commercial-stage biopharmaceutical company focused on rare diseases, announced that its executive leadership will present at three major healthcare investor conferences in New York in September 2026. These presentations aim to update investors on the company's progress and strategic direction. Zevra's lead product targets Niem…
OptimizeRx Corp. has appointed Troy Sarich, an expert in pharmaceutical commercialization and artificial intelligence, as a company advisor. Sarich's extensive experience at Johnson & Johnson and deep expertise in data analytics will help OptimizeRx enhance its healthcare technology solutions, facilitating better engagement between life sciences br…
BridgeBio Pharma announced they will present new late-breaking and longer-term data on oral infigratinib, a drug targeting achondroplasia, at the Annual European Society for Paediatric Endocrinology Meeting 2026. The data include results from the PROPEL 3 randomized controlled trial, longer-term safety and efficacy findings, and ongoing studies in …
Telesat Corporation and Farcast have completed a successful demonstration of Farcast's electronically steered antenna technology using Telesat's LEO 3 test satellite. This milestone validates Farcast's architecture, which reduces size, weight, power, and cost while maintaining performance, and sets the stage for integrating this technology into a f…
Kyntra Bio, a biopharmaceutical company focused on oncology and rare diseases, announced management will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will cover company developments, including updates on their anemia treatment Roxadustat and Phase 2 ADC therapy FG-3246 for prostate cancer.
Palvella Therapeutics, a clinical-stage biotech company targeting rare skin diseases and vascular malformations, announced CEO Wes Kaupinen’s participation in two healthcare investor conferences in September 2026. The company highlighted its lead candidates, QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin, which are investigational th…
Purple Biotech Ltd. announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering tri-specific antibody constructs under its CAPTN-3 platform. This patent strengthens the company's intellectual property protection for its modular multispecific antibody technology designed to accelerate development of cancer i…
Edible Garden AG Incorporated has officially regained compliance with Nasdaq’s minimum bid price rule, enabling it to maintain its listing and focus on executing growth strategies including expanding its Webster City facility to manufacture ready-to-drink nutrition products and advancing its Farm-to-Formula® platform.
Lifecore Biomedical has signed a significant agreement to perform tech transfer and commercial manufacturing for a commercially marketed injectable drug product from a global pharmaceutical company. This program, expected to generate revenue starting in 2028, further strengthens Lifecore's late-stage commercial pipeline and expands its customer bas…
uniQure has submitted a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorisation Application (MAA) to the U.K.'s MHRA for its investigational gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. The applications are based on three-year Phase I/II study data showing slowed disease progression and the c…
Teva Pharmaceutical Industries announced positive topline Phase 2a study results for TEV-408, an investigational anti-IL-15 antibody. The drug showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage in celiac disease patients, with a favorable safety profile. TEV-408 also demonstrated a reduction in…
European Wax Center, a leading US waxing services franchisor, has introduced the Golden Orchard Body Butter and Body Polish, limited-edition fall skincare products designed to hydrate, exfoliate, and nourish skin while reducing hair thickness between waxes, expanding its SLOW Hair Minimizing System.
Cardiff Oncology announced that their Ph.D. Mani Mohindru will present at the 8th Annual RAS-Targeted Drug Development Summit and participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company focuses on developing PLK1 inhibition therapies, including its lead candidate onvansertib, targeting RAS-mutated…
G-III Apparel Group reported second quarter fiscal 2027 net income per diluted share of $0.46, surpassing guidance and nearly doubling last year's $0.25. Despite a 10% decline in net sales due to Calvin Klein and Tommy Hilfiger license losses, gross margins expanded by 440 basis points. The company completed the acquisition of Marc Jacobs, targetin…
Maze Therapeutics, a clinical-stage biopharmaceutical company focused on small molecule precision medicines for kidney and metabolic diseases, announced that management will participate in three investor conferences in early to mid-September 2026, including Wells Fargo Healthcare Conference, Citi Biopharma Summit, and HC Wainwright Global Investmen…
TScan Therapeutics announced a strategic reorganization to concentrate resources on developing in vivo engineered TCR-T cell therapies for solid tumors, advancing two candidates toward IND-enabling studies and planned Phase 1 trials by late 2027. Due to insufficient capital, the company has paused enrollment in the Phase 3 ALLOHA-2 study for TSC-10…
Tilray Brands, Inc. announced that due to strong consumer demand, its Popsicle Hard Firecracker flavor, originally a limited-edition seasonal product, will become a permanent offering in the Popsicle Hard malt beverage lineup. This move reflects the brand's strategy to leverage nostalgia-driven flavors to capture growth in the adult flavored bevera…
Ollie’s Bargain Outlet Holdings, Inc. announced its second quarter fiscal 2026 financial results, revealing a 9.1% increase in net sales to $741.3 million driven by new store openings and growth in loyalty members. Comparable store sales declined 1.8% due to challenging economic conditions, weather impact, and a competitive promotional environment.…
GXO Logistics, the world's largest pure-play contract logistics provider, announced that its executive leadership will participate in upcoming investor conferences, including the Jefferies Global Industrials Conference and the Morgan Stanley 14th Annual Laguna Conference. The company will showcase its strategies and business updates through present…
EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company focused on retinal diseases, announced its active participation in several upcoming investor conferences and The Retina Society 59th Annual Scientific Meeting, where it will present data on its lead product candidate DURAVYU (EYP-1901). DURAVYU is a sustained delivery treatme…
Fortrea has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials, including a clinical pharmacology unit, bioanalytical laboratory, and biospecimen storage facilities in Texas. This acquisition strengthens Fortrea’s integrated clinical development platform from first-in-human studies through Phase …
